KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $128000.0.

  • TherapeuticsMD's Other Operating Expenses rose 3333.33% to $128000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $514000.0, marking a year-over-year decrease of 7937.4%. This contributed to the annual value of $1.8 million for FY2024, which is 11618.0% up from last year.
  • Latest data reveals that TherapeuticsMD reported Other Operating Expenses of $128000.0 as of Q3 2025, which was up 3333.33% from $96000.0 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Other Operating Expenses ranged from a high of $143.4 million in Q2 2022 and a low of -$93.3 million during Q4 2021
  • For the 5-year period, TherapeuticsMD's Other Operating Expenses averaged around $9.9 million, with its median value being $183000.0 (2025).
  • Per our database at Business Quant, TherapeuticsMD's Other Operating Expenses plummeted by 45882.06% in 2021 and then soared by 34579.03% in 2022.
  • Over the past 5 years, TherapeuticsMD's Other Operating Expenses (Quarter) stood at -$93.3 million in 2021, then surged by 110.79% to $10.1 million in 2022, then tumbled by 91.83% to $822000.0 in 2023, then plummeted by 86.98% to $107000.0 in 2024, then grew by 19.63% to $128000.0 in 2025.
  • Its Other Operating Expenses was $128000.0 in Q3 2025, compared to $96000.0 in Q2 2025 and $183000.0 in Q1 2025.